NCT06787755 is a clinical trial in COVID - 19, sponsored by Fayoum University.

Who is sponsoring NCT06787755?

NCT06787755 is sponsored by Fayoum University.

What condition does NCT06787755 study?

NCT06787755 studies COVID - 19.

Is NCT06787755 still recruiting?

NCT06787755 is currently completed. Last updated 22 January 2025.

Last reviewed 2025-01-22 · How we verify

NCT06787755

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Persistent COVID-19 Symptoms in Minia

Completed Last updated 22 January 2025

What this trial tests

trial in COVID - 19 in 189 participants. Completed in 10 September 2024.

Timeline

10 March 2021

Primary endpoint
10 September 2023

10 September 2024

Quick facts

Lead sponsor	Fayoum University
Status	Completed
Study type	OBSERVATIONAL
Enrollment	189
Start date	10 March 2021
Primary completion	10 September 2023
Estimated completion	10 September 2024
Sites	1 location across Egypt

Conditions studied

COVID - 19 — all drugs for COVID - 19 →

Sponsor

Fayoum University

Who can join

Adults 18 to 75, any sex, with COVID - 19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Objective This study aims to identify the nature and prevalence of persistent symptoms in patients discharged from Minya University hospitals in Egypt after recovery from COVID-19, the severity of these symptoms, and the possible risk factors associated with them.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for COVID - 19

Currently open trials in the same condition.

NCT07197164 — Safety and Effectiveness of a Remdesivir Treatment to Prevent Severe COVID-19 in Kidney Transplant Patients · Phase 2 · recruiting
NCT07150871 — Impact of Covid-19 on Syphilis · active not recruiting
NCT07204366 — Autoantibodies Against Type I Interferon in Patients Affected With Ph-negative Myeloproliferative Neoplasms (MPN-IFN Stu · active not recruiting

Other Fayoum University trials

Trials by the same sponsor.

NCT07536620 — Metformin and Alveolar Cleft · Phase 2 · not yet recruiting
NCT07444970 — Comparative Evaluation of Xenograft Alone and Sticky Bone in Sinus Lift With Concurrent Implant Placement · NA · not yet recruiting
NCT07394179 — Transforming Channel Osteotomy Into Tunnel Osteotomy in Zygomatic Implant Preparation · NA · not yet recruiting
NCT07277348 — Analysis of The Outcomes of Therapeutic Photorefractive Keratectomy Combined With Prophylactic Accelerated Cross-Linking · NA · not yet recruiting
NCT07330726 — Lidocaine Patch and Lower Third Molar · Phase 3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06787755 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fayoum University
Last refreshed: 22 January 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06787755.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing